# ONC201 in Adults With Recurrent H3 K27M-mutant Glioma

> **NCT03295396** · PHASE2 · TERMINATED · sponsor: **Jazz Pharmaceuticals** · enrollment: 73 (actual)

## Conditions studied

- Glioma

## Interventions

- **DRUG:** Dordaviprone (ONC201)

## Key facts

- **NCT ID:** NCT03295396
- **Lead sponsor:** Jazz Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-10-30
- **Primary completion:** 2022-12-31
- **Final completion:** 2023-07-19
- **Target enrollment:** 73 (ACTUAL)
- **Why stopped:** The Sponsor terminated the study to prioritize enrollment in a randomized Phase 3 trial of ONC201 in an earlier setting. This decision was unrelated to any safety concerns with dordaviprone (ONC201).
- **Last updated:** 2025-07-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03295396

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03295396, "ONC201 in Adults With Recurrent H3 K27M-mutant Glioma". Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/clinical/NCT03295396. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*